Sökning: WFRF:(Myhr Eriksson Kristina) >
Long-term tolerabil...
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
-
- Flygt, Hjalmar (författare)
- Uppsala universitet,Hematologi
-
- Söderlund, Stina (författare)
- Uppsala universitet,Hematologi
-
- Stentoft, Jesper (författare)
- Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark.
-
visa fler...
-
- Richter, Johan (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.
-
- Koskenvesa, Perttu (författare)
- Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.
-
- Mustjoki, Satu (författare)
- Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland.;Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Translat Immunol Res Program, Helsinki, Finland.;Univ Helsinki, Dept Clin Chem & Hematol, Helsinki, Finland.
-
- Majeed, Waleed (författare)
- Stavanger Univ Hosp, Dept Hematooncol, Stavanger, Norway.
-
- Lübking, Anna (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.
-
- Dreimane, Arta (författare)
- Linköping Univ Hosp, Dept Hematol, Linköping, Sweden.
-
- Markevärn, Berit (författare)
- Umeå Univ Hosp, Dept Hematol, Umeå, Sweden.
-
- Stenke, Leif (författare)
- Karolinska Institutet
-
- Myhr Eriksson, Kristina (författare)
- Sunderby Hosp, Dept Internal Med & Hematol, Luleå, Sweden.
-
- Gjertsen, Bjørn Tore (författare)
- Haukeland Hosp, Hematol Sect, Dept Internal Med, Bergen, Norway.
-
- Gedde-Dahl, Tobias (författare)
- Natl Hosp Norway, Oslo Univ Hosp, Dept Hematol, Oslo, Norway.
-
- Dimitrijevic, Andreja (författare)
- Odense Univ Hosp, Dept Hematol, Odense, Denmark.
-
- Udby, Lene (författare)
- Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark.
-
- Olsson-Strömberg, Ulla (författare)
- Uppsala universitet,Hematologi
-
- Hjorth-Hansen, Henrik (författare)
- St Olavs Hosp Trondheim, Dept Hematol, Trondheim, Norway.;Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway.
-
visa färre...
-
(creator_code:org_t)
- 2021-08-31
- 2021
- Engelska.
-
Ingår i: European Journal of Haematology. - : John Wiley & Sons. - 0902-4441 .- 1600-0609. ; 107:6, s. 617-623
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- ObjectivesTreatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-α in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-α (PegIFN-α) in combination with dasatinib (DAS) in CML-CP.MethodsForty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 μg/wk of PegIFN-α was added and increased to 25 μg/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data.ResultsAfter 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study.ConclusionInitial addition of PegIFN-α to DAS shows good long-term efficacy without increased toxicity.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- BCR-ABL Positive
- chronic myelogenous leukemia
- clinical trial
- dasatinib
- interferon-alpha
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Flygt, Hjalmar
-
Söderlund, Stina
-
Stentoft, Jesper
-
Richter, Johan
-
Koskenvesa, Pert ...
-
Mustjoki, Satu
-
visa fler...
-
Majeed, Waleed
-
Lübking, Anna
-
Dreimane, Arta
-
Markevärn, Berit
-
Stenke, Leif
-
Myhr Eriksson, K ...
-
Gjertsen, Bjørn ...
-
Gedde-Dahl, Tobi ...
-
Dimitrijevic, An ...
-
Udby, Lene
-
Olsson-Strömberg ...
-
Hjorth-Hansen, H ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet